Hematologic Oncology

Axi-cel led to higher response rates but increased toxicity vs tisa-cel in older patients with relapsed/refractory DLBCL.

A consistent ORR was shown with axatilimab after second-line therapy, regardless of prior lines of therapy, in patients with steroid-refractory cGVHD.

Infections occur early after CAR T-cell therapy administration in patients with relapsed/refractory NHL.

Orca-T improved moderate-to-severe cGVHD–free survival vs conventional allogenic transplant in advanced hematologic malignancies.

Obe-cel showed higher response rates and longer survival vs non–CAR T therapies in adults with R/R B-ALL.

The addition of inotuzumab ozogamicin to bridging therapy led to high objective response rates and sustained survival in obe-cel recipients with B-cell ALL.

A donor-derived CAR T-cell therapy produced complete remissions, but survival was limited in relapsed/refractory T-cell lymphoma.

Stable disease was common in patients with CD123-positive, relapsed/refractory acute myeloid leukemia who were treated with AFM28.

Ioannis Politikos, MD, discusses data from a study which compared the immune reconstitution profiles of Orca-T with those from CD34 allograft recipients.

TDI01, a selective ROCK2 inhibitor, generated responses and clinical benefit in patients with cGVHD.

Acimtamig plus AlloNK was associated with high objective response rates in heavily pretreated patients with relapsed/refractory Hodgkin lymphoma.

A comparative analysis showed that apraglutide plus ruxolitinib improved response rates vs ruxolitinib monotherapy in steroid-refractory GI aGVHD.

Orca-T was associated with a retrospective survival improvement vs post-transplant cyclophosphamide in advanced hematologic malignancies.

Orca-T led to lower rates of EBV and CMV reactivation vs CD34 engraftment in patients with select hematologic malignancies.

Higher CR rates were achieved with the tandem CAR T-cell infusion plus ASCT vs the infusion alone in patients with relapsed/refractory B-cell lymphoma.

Esther Natalie Oliva, MD, discusses the rationale for the phase 3 QuANTUM-Wild trial in newly diagnosed FLT3-ITD–negative AML.

The FDA cleared therapeutic options in pNETs/epNETs, MIBC, and mCRPC; experts highlight top abstracts ahead of 2025 EBMT; and more from OncLive.

Gregory Roloff, MD, highlights ongoing frontline TKI research in Ph-positive ALL and why he uses a newer-generation TKI over imatinib.

The day-29 ORR and CR rate was not met with frontline itolizumab vs placebo in patients with acute graft-vs-host disease enrolled in the phase 3 EQUATOR trial.

Drs Park and LaCasce discuss advancements in Hodgkin and non-Hodgkin lymphoma management, including efforts to reduce long-term toxicity.

Jenny Paredes, PhD, discusses how increased dietary fiber was associated with improved 24-month survival and reduced lower GI aGVHD in allo-HCT recipients.

Eunice S. Wang, MD, discusses the role of menin inhibitors like revumenib in AML with KMT2A rearrangements or NPM1 mutations.

Median PFS and OS were comparable between age groups when CAR T-cell therapy was given as treatment for patients with relapsed/refractory LBCL.

Olalekan O. Oluwole, MD, discusses research findings showing that patients with LBCL may not need prolonged hospital monitoring following axi-cel infusion.

The risk of developing ICANS with CAR T-cell therapy was higher in patients with NHL who experienced a recent fall and could not balance on their left leg.